Sartorius Stedim Biotech SA (DIM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sartorius Stedim Biotech SA (DIM) has a cash flow conversion efficiency ratio of 0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€60.40 Million) by net assets (€4.07 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sartorius Stedim Biotech SA - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Sartorius Stedim Biotech SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sartorius Stedim Biotech SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sartorius Stedim Biotech SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Reliance Steel & Aluminum Co
NYSE:RS
|
0.036x |
|
NIO Inc.
BA:NIO
|
N/A |
|
ZSCALER INC. DL-,001
XETRA:0ZC
|
0.093x |
|
Rongsheng Petrochemical Co Ltd
SHE:002493
|
0.167x |
|
China Shipbuilding Industry Co Ltd
SHG:601989
|
-0.021x |
|
DESTEK FINANS FAKTORING
IS:DSTKF
|
-0.264x |
|
China Overseas Land & Investment Limited
F:CPP
|
0.040x |
|
Lennox International Inc
NYSE:LII
|
0.339x |
Annual Cash Flow Conversion Efficiency for Sartorius Stedim Biotech SA (2005–2024)
The table below shows the annual cash flow conversion efficiency of Sartorius Stedim Biotech SA from 2005 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €4.02 Billion | €815.10 Million | 0.203x | -27.45% |
| 2023-12-31 | €2.67 Billion | €746.40 Million | 0.279x | +14.65% |
| 2022-12-31 | €2.51 Billion | €612.30 Million | 0.244x | -39.35% |
| 2021-12-31 | €1.73 Billion | €695.97 Million | 0.402x | +42.84% |
| 2020-12-31 | €1.48 Billion | €416.88 Million | 0.281x | +6.75% |
| 2019-12-31 | €1.18 Billion | €310.13 Million | 0.263x | +21.07% |
| 2018-12-31 | €1.04 Billion | €227.29 Million | 0.218x | +9.51% |
| 2017-12-31 | €879.45 Million | €174.69 Million | 0.199x | -3.19% |
| 2016-12-31 | €763.56 Million | €156.66 Million | 0.205x | -7.00% |
| 2015-12-31 | €647.22 Million | €142.79 Million | 0.221x | +6.73% |
| 2014-12-31 | €538.51 Million | €111.31 Million | 0.207x | +10.53% |
| 2013-12-31 | €481.84 Million | €90.11 Million | 0.187x | +66.16% |
| 2012-12-31 | €434.72 Million | €48.93 Million | 0.113x | -26.52% |
| 2011-12-31 | €395.63 Million | €60.59 Million | 0.153x | -23.15% |
| 2010-12-31 | €365.07 Million | €72.76 Million | 0.199x | -14.69% |
| 2009-12-31 | €393.20 Million | €91.86 Million | 0.234x | +83.84% |
| 2008-12-31 | €371.65 Million | €47.23 Million | 0.127x | +77.15% |
| 2007-12-31 | €362.76 Million | €26.02 Million | 0.072x | -76.57% |
| 2006-12-31 | €168.93 Million | €51.72 Million | 0.306x | +3.56% |
| 2005-12-31 | €148.35 Million | €43.85 Million | 0.296x | -- |
About Sartorius Stedim Biotech SA
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more